Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

LOXO-783

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

PI3Kα H1047R mutation inhibitor

Related drugs:

‹

›

HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G	HER2 Negative Breast Cancer	HR positive + PIK3CA H1047R + PIK3CA D350G + ER D538G	HER2 Negative Breast Cancer	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D
HR positive + PIK3CA H1047R + ER D538G	HER2 Negative Breast Cancer	HR positive + PIK3CA H1047R + ER D538G	HER2 Negative Breast Cancer	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D
HR positive + PIK3CA H1047R	HER2 Negative Breast Cancer	HR positive + PIK3CA H1047R	HER2 Negative Breast Cancer	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D	LOXO-783 Sensitive: D – Preclinical LOXO-783 Sensitive : D